A Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-Line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer (INTR@PID)
A Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-Line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer (INTR@PID)
Trial Category:
Lung
Phase
II
Contact(s)
Location(s)
Southeast Nebraska Cancer Center, Lincoln, NE
This study is looking at the drug M7824 versus Pembrolizumab for first treatment of patients diagnosed with advanced lung cancer. This is an open-label study meaning that you will know what drug you are assigned to receive. Patients are "randomized" on this study. This means a computer tells the study team which treatment you will receive. Neither the patient or the physician can choose the treatment assignment. The purpose of Randomized trials is to equally study both treatment options using the same criteria in order to identify if one treatment may be superior to another treatment.
